Market Analysis and Insights:
The market for Global Myomectomy was estimated to be worth USD 1.23 billion in 2022, and from 2024 to 2032, it is anticipated to grow at a CAGR of 5.93%, with an expected value of USD 1.86 billion in 2032.
The global myomectomy industry is experiencing growth due to a variety of factors. A primary driver is the increasing prevalence of uterine fibroids, a common condition affecting a significant number of women globally. Myomectomy, a surgical procedure aimed at removing noncancerous uterine tumors, is frequently performed to address this issue. Another contributing factor is the mounting awareness of myomectomy's advantages in preserving fertility, making it a preferred choice for many women over hysterectomy, as it enables them to maintain their reproductive capabilities. Furthermore, advancements in surgical techniques, icularly in minimally invasive procedures, have enhanced the accessibility and safety of myomectomy, fostering market expansion. Additionally, the demand for personalized healthcare and the availability of advanced medical facilities in developed regions are driving forces in the market. Nonetheless, challenges such as the high cost of the procedure and alternative treatment options could impede market growth. Nevertheless, ongoing research and development initiatives are expected to propel the myomectomy market's continued expansion in the foreseeable future.
Myomectomy Market Scope:
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2032 |
| Study Period | 2018-2032 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2032 | USD 1.86 billion |
| Growth Rate | CAGR of 5.93% during 2024-2032 |
| Segment Covered | By Product, By Type, By End-use, By Region. |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | MEDTRONIC PLC, ETHICON, INC., COOPER SURGICAL, INC., OLYMPUS CORPORATION, HOSPIRA, INC., KARL STORZ SE & CO KG, B. BRAUN MELSUNGEN AG, MEDGYN PRODUCTS, INC., CONMED CORPORATION, and MAXER ENDOSCOPY GMBH. |
Market Definition
Myomectomy is a surgical intervention focused on excising benign uterine growths commonly referred to as fibroids, serving as a viable choice for women aiming to maintain their reproductive capabilities.
The primary objective of this procedure is to alleviate issues like intense menstrual bleeding, pelvic discomfort, and abdominal pressure.
Myomectomy stands as a significant surgical intervention employed in addressing uterine fibroids, benign growths that can lead to complications such as excessive menstruation, pelvic discomfort, and infertility. This procedure entails the excision of fibroids while safeguarding the integrity of the uterus, with the primary goal of mitigating symptoms and enhancing the overall quality of life for impacted individuals. As opposed to alternatives like hysterectomy, myomectomy presents the advantage of preserving fertility prospects for women desiring future conception. Moreover, it offers relief from fibroid-induced manifestations, enabling women to restore both their physical and mental well-being. Thorough examination reveals that myomectomy plays a pivotal role in meeting the unique requirements and concerns of women battling uterine fibroids, thus serving as an indispensable and advantageous approach for managing this condition.
Key Market Segmentation:
Insights On Key Product
Laparoscopic Power Morcellators Laparoscopic power morcellators are expected to dominate the Global Myomectomy Market. These devices are widely used in minimally invasive surgeries to remove fibroids.
They offer advantages such as shorter recovery time, smaller incisions, and reduced postoperative pain. The increasing prevalence of uterine fibroids and the growing preference for minimally invasive procedures are driving the demand for laparoscopic power morcellators in myomectomy surgeries. Additionally, advancements in technology have further improved the safety and efficacy of these devices, making them a preferred choice for surgeons.
Harmonic Scalpel
Harmonic scalpel is another important part of the By Product in the Global Myomectomy Market. This device utilizes ultrasonic energy to simultaneously cut and coagulate tissue during myomectomy procedures. While harmonic scalpel offers precise tissue dissection and hemostasis, its usage is more common in other surgical procedures compared to myomectomy. Therefore, though harmonic scalpel plays a significant role in surgical settings, it is not expected to dominate the Global Myomectomy Market.
Laparoscopic Sealer
Laparoscopic sealer is a of the By Product in the Global Myomectomy Market. These devices are utilized in sealing blood vessels or tissue during myomectomy procedures. While laparoscopic sealers are essential tools for achieving hemostasis during surgery, they do not have the same level of dominance as laparoscopic power morcellators. The demand for laparoscopic sealers is significant, but it is expected to be surpassed by the popularity and widespread usage of laparoscopic power morcellators.
Others
The "Others" refers to other types of devices or instruments used in myomectomy procedures, which are not specific to laparoscopic power morcellators, harmonic scalpel, or laparoscopic sealer. This category may include traditional surgical instruments, manual tissue morcellators, suture materials, and other related products. While these devices are essential components of myomectomy surgeries, they are not expected to dominate the Global Myomectomy Market due to the increasing adoption of minimally invasive procedures and the higher prevalence of laparoscopic power morcellators as the preferred choice among surgeons.
Insights On Key Type
Laparoscopic myomectomy.
Laparoscopic myomectomy is expected to dominate the Global Myomectomy Market. This utilizes minimally invasive surgical techniques, which involve making small incisions in the abdomen and using a laparoscope to remove uterine fibroids. Laparoscopic myomectomy offers several advantages over other types of myomectomy, including shorter hospital stays, faster recovery times, reduced blood loss, and lower risks of complications. These benefits have led to an increasing preference for laparoscopic myomectomy among patients and healthcare providers. Additionally, advancements in technology and surgical instruments have improved the precision and effectiveness of laparoscopic myomectomy procedures, further driving its dominance in the market.
Abdominal myomectomy.
Abdominal myomectomy, although not expected to dominate the Global Myomectomy Market, remains a significant . This type of myomectomy involves a larger abdominal incision, allowing surgeons better access to remove large or multiple uterine fibroids. Abdominal myomectomy is often preferred in cases where fibroids are complex or extensive, and laparoscopic or hysteroscopic approaches may not be suitable. Despite its invasiveness and longer recovery times compared to other s, abdominal myomectomy maintains its relevance due to its efficacy in handling challenging fibroid cases.
Hysteroscopic myomectomy.
Hysteroscopic myomectomy is one more noticeable within the Global Myomectomy Market. This procedure involves the removal of uterine fibroids using a hysteroscope inserted through the vagina and cervix. Hysteroscopic myomectomy is generally recommended for smaller fibroids that are located within the uterine cavity. It is a minimally invasive approach, offering advantages such as shorter recovery times, minimal scarring, and reduced post-operative pain. While hysteroscopic myomectomy provides effective treatment for certain fibroids, its applicability is limited to specific cases, such as submucosal or intracavitary fibroids. Therefore, it is not expected to dominate the market but still serves as a valuable option for suitable patients.
Insights On Key End-use
Hospitals & Clinics
Hospitals and clinics are expected to dominate the Global Myomectomy Market. Myomectomy is a surgical procedure performed to remove uterine fibroids, and hospitals and clinics are typically the primary facilities where such surgeries are conducted. These healthcare settings have the necessary infrastructure, equipment, and expertise to perform myomectomies effectively and safely. Hospitals, in icular, have dedicated gynecology de ments and specialized surgeons who are experienced in performing myomectomy procedures. The availability of advanced medical technology, intensive care units, and round-the-clock medical support also make hospitals and clinics the preferred choice for patients undergoing myomectomy.
Ambulatory Surgical Centers
Ambulatory surgical centers are an important of the Global Myomectomy Market. These healthcare facilities provide same-day surgical procedures, including myomectomy, without the need for overnight hospital stays. Ambulatory surgical centers offer several advantages, such as lower costs, convenience, and reduced risk of exposure to hospital-acquired infections. They are well-suited for patients with relatively uncomplicated cases of uterine fibroids who do not require extensive post-operative care. While ambulatory surgical centers provide a viable option for myomectomy, they may not be as widely available or have the same level of resources and specialization as hospitals and clinics.
Others
The "Others" within the By End-use category of the Global Myomectomy Market refers to alternative healthcare facilities or settings that may also offer myomectomy procedures but are not classified as hospitals, clinics, or ambulatory surgical centers. These could include specialty centers, private surgical suites, or outpatient units associated with larger medical organizations. While there may be a niche market for myomectomy in these settings, they are unlikely to dominate the overall market. These "Others" may cater to specific patient populations or offer unique advantages, such as personalized care or innovative surgical techniques. However, due to their limited reach and specialized nature, they are not expected to overshadow the dominant position of hospitals and clinics in the Global Myomectomy Market.
Insights on Regional Analysis:
Europe
Europe is expected to dominate the Global Myomectomy market. The dominant position of Europe can be attributed to several factors. Firstly, the region has a well-established healthcare infrastructure and a high level of awareness about gynecological procedures. This creates a favorable environment for the adoption of myomectomy procedures. Additionally, Europe is witnessing a high prevalence of uterine fibroids, which is a major indication for myomectomy surgery. Moreover, favorable reimbursement policies and increasing investments in research and development activities further contribute to the growth of the myomectomy market in Europe.
North America
North America, the myomectomy market is expected to experience significant growth. The region has a high prevalence of uterine fibroids, which fuels the demand for myomectomy procedures. Furthermore, advanced healthcare facilities and a well-established reimbursement system in countries like the United States and Canada act as key drivers for market growth. Additionally, rising awareness about women's health and increasing emphasis on early diagnosis and treatment of fibroids further contribute to the dominance of North America in the global myomectomy market.
Asia Pacific
Asia Pacific is projected to witness substantial growth in the myomectomy market. Factors such as a large population base, increasing healthcare expenditure, and rising awareness about gynecological disorders drive the growth of the market in this region. Moreover, improving healthcare infrastructure and the availability of skilled healthcare professionals contribute to the increasing adoption of myomectomy procedures in Asian countries. Additionally, a surge in disposable income levels and a growing middle-class population further support the expansion of the myomectomy market in Asia Pacific.
Latin America
While Latin America shows promising growth potential in the myomectomy market, it is not expected to dominate on a global scale. However, countries like Brazil, Mexico, and Argentina are witnessing increasing investments in healthcare infrastructure and growing awareness about women's health, contributing to the market growth in the region.
Middle East & Africa
The Middle East & Africa region is anticipated to witness moderate growth in the myomectomy market. Factors such as increasing healthcare expenditure, rising prevalence of uterine fibroids, and improving access to healthcare facilities contribute to the growth of the market in this region. However, compared to other regions, Middle East & Africa has relatively lower market share due to challenges such as limited awareness about myomectomy procedures and resource constraints in certain countries. Nevertheless, ongoing developments in healthcare infrastructure and initiatives taken to enhance women's healthcare services are expected to drive market growth in the Middle East & Africa region.
Company Profiles:
Prominent contributors within the international Myomectomy sector significantly influence market progression and advancement with their focus on research and development, expansion of product offerings, and strategic nerships. Their emphasis on delivering cutting-edge surgical procedures and efficient uterine fibroids treatments not only addresses the changing requirements of healthcare practitioners and patients but also propels market growth and innovation. Prominent companies in the field of Myomectomy comprise MEDTRONIC PLC, ETHICON, INC., COOPER SURGICAL, INC., OLYMPUS CORPORATION, HOSPIRA, INC., KARL STORZ SE & CO KG, B. BRAUN MELSUNGEN AG, MEDGYN PRODUCTS, INC., CONMED CORPORATION, and MAXER ENDOSCOPY GMBH.
COVID-19 Impact and Market Status:
The COVID-19 pandemic has imposed a notable impact on the global myomectomy market, causing a decrease in market revenues due to the postponement of elective surgeries and decreased patient consultations. The global market for myomectomy has been significantly impacted by the ongoing COVID-19 pandemic. Myomectomy, a surgical intervention to remove uterine fibroids, benign tumors in the uterus, has been icularly affected. The surge in COVID-19 cases has overwhelmed healthcare facilities worldwide, leading to the postponement or cancellation of elective procedures such as myomectomies. Consequently, there has been a notable reduction in the number of myomectomy surgeries performed, directly affecting the demand for related products and services. The apprehension of contracting the virus has also dissuaded patients from seeking medical care unless absolutely necessary, further stunting market growth. Furthermore, disruptions in the supply chain caused by lockdowns and transport constraints have caused delays or shortages in the availability of crucial medical equipment required for myomectomy procedures. Consequently, the myomectomy market has experienced a slowdown in its growth trajectory during the pandemic. Nonetheless, with the gradual recovery of global healthcare systems and economies, it is anticipated that the myomectomy market will gradually regain its momentum.
Latest Trends and Innovation:
- In 2019, Medtronic, a global medical device company, acquired Acessa Health Inc., a leading company in minimally invasive uterine fibroid solutions, to enhance its portfolio of women's health solutions.
- In July 2020, CooperSurgical, a leading global medical device company, announced the acquisition of Biopsy Sciences, a innovative company specializing in uterine therapy products and devices.
- In April 2021, Boston Scientific, a renowned medical technology company, launched its MyoSure Manual Device, an innovative solution for the removal of uterine fibroids, demonstrating their commitment to advancing myomectomy procedures.
- In September 2021, Hologic Inc., a leading manufacturer of diagnostic and surgical products, announced the launch of Omni hysteroscope, a flexible hysteroscope designed for easier access and improved visualization during myomectomy procedures.
- In October 2021, Johnson & Johnson's Ethicon division announced the acquisition of Auris Health, a robotic platform developer, to incorporate advanced robotics technologies into their surgical devices, potentially benefiting myomectomy procedures in the future.
Significant Growth Factors:
The rising frequency of uterine fibroids and progress in surgical methods are significant factors fueling the expansion of the Myomectomy Market. The Myomectomy Market is experiencing remarkable growth driven by several key factors. These include the rising global prevalence of uterine fibroids, advancements in surgical methods, increased awareness among women regarding minimally invasive procedures, and escalating healthcare expenditure. Uterine fibroids are a common issue among women of reproductive age, leading to symptoms like heavy menstrual bleeding, pelvic pain, and infertility. The surge in uterine fibroid cases is fueling the demand for myomectomy procedures. Moreover, the technological progress in surgical approaches, including laparoscopic and robotic-assisted myomectomy, has enhanced surgical outcomes, lessened patient discomfort, and decreased hospital stays. These advancements have propelled many patients towards less invasive treatment alternatives. In addition, the growing awareness among women about available treatment options for uterine fibroids, coupled with the benefits of myomectomy, has played a significant role in driving market expansion. Increased healthcare spending and supportive reimbursement policies have also fostered the growth of the myomectomy market, making the procedure more accessible to patients and encouraging healthcare providers to offer necessary facilities and technologies. In conclusion, the myomectomy market is poised for substantial growth in the foreseeable future due to the rising prevalence of uterine fibroids, advancements in surgical techniques, increased awareness among women, and favorable reimbursement policies.
Restraining Factors:
The Myomectomy market faces significant constraints due to the scarcity of skilled surgeons and the elevated costs associated with the procedure. The growth of the myomectomy market is hindered by various factors. One key obstacle is the high cost associated with myomectomy procedures, deterring patients from seeking treatment due to the prohibitive expenses related to surgery, hospitalization, and follow-up care. Limited access to advanced healthcare facilities in rural areas exacerbates this issue, along with a shortage of skilled professionals trained in performing myomectomy procedures. The lengthy recovery time and potential for post-surgery complications also discourage some patients from opting for myomectomy. Furthermore, the rising popularity of alternative treatments like medication or minimally invasive procedures poses a competitive challenge to the myomectomy market, offering faster recovery and lower costs to patients. Despite these challenges, the myomectomy market still harbors growth potential. Technological advancements and improved surgical techniques, coupled with increased healthcare investments, can help reduce costs and enhance accessibility to myomectomy procedures. Raising awareness about the benefits of myomectomy and its effectiveness in managing various health conditions can also address the market's challenges effectively.
Key Segments of the Myomectomy Market :
Product Overview
• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer
• Others
Type Overview
• Abdominal Myomectomy
• Hysteroscopic Myomectomy
• Laparoscopic Myomectomy
End-Use Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others
Regional Overview
North America
• US
• Canada
• Mexico
Europe
• Germany
• France
• U.K
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
Middle East and Africa
• Saudi Arabia
• UAE
• Rest of Middle East and Africa
Latin America
• Brazil
• Argentina
• Rest of Latin America
Frequently Asked Questions (FAQ) :
The market value of myomectomy market in 2032 was USD 1.86 billion
The base year for the report is 2023 in myomectomy market.
Recent ultrasound data suggested a cumulative incidence at least 70%, uterine myoma originating from the myometrium of the uterus is the most common benign tumor in women with prevalence rates ranging from 20% to 40% are noted in different literatures though the incidence as per the histological diagnosis is much more than the clinical diagnosis which approximately 60% of women above 45 years of age are harboring myoma. Myoma is mostly asymptomatic. Size and location are the main factors that determine if a myoma leads to symptoms and problems. Important symptoms include abnormal uterine bleeding, abdominal discomfort, bloating, painful defecation, backache, urinary frequency or retention and infertility. It is associated with impairment of Health-Related Quality of Life. The presence of submucous and intramural myoma decreases fertility and its removal is beneficial. Patients have multiple options in the management of uterine myomas including observation, medical therapy, uterine artery embolization, high intensity focused ultrasound ablation and as well as surgical methods like Myomectomy and hysterectomy. Surgical removal is necessary when the myoma is symptomatic and resistant to medical management or interferes with reproduction. Although uterine artery embolization is now an effective way for managing symptomatic uterine myomas but its effect on future conception remains unclear.
On the basis of type, the market is segmented into abdominal, laparoscopic and hysteroscopic Myomectomy. The abdominal Myomectomy segment led the market in 2020. More commonly Myomectomy operation is performed by abdominal incision where the layered closure of uterus can be achieved easily; laparoscopic Myomectomy requires additional equipment’s whereas results of robotic Myomectomy are yet to be proved better than laparoscopic method, but in hysterectomy, blood transfusions, scar dehiscence in future pregnancy and many others has not yet been evaluated. Among available treatment modalities of which mostly in symptomatic myomas where open Myomectomy is the most likely treatment option despite of introduction of nonsurgical and newer methods available worldwide, where hemorrhagic complication that controlled by different techniques though individuals having drawbacks but the bilateral uterine arteries ligation not only very effective to minimize blood loss but also safe and no adverse effects on fertility and pregnancy.
North America accounted for the largest share of the global Myomectomy market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period.
With fibroids as the indication for surgery, 197,000 hysterectomies were performed in the United States in 2010, compared with approximately 40,000 myomectomies. Moreover, the rates of both laparoscopic and abdominal Myomectomy have decreased following the controversial morcellation advisory issued by the US Food and Drug Administration. The differences in the hysterectomy and Myomectomy rates might be explained by the many myths ascribed to Myomectomy. Such myths include the beliefs that Myomectomy, when compared with hysterectomy, is associated with greater risk of visceral injury, more blood loss, poor uterine healing, and high risk of fibroid recurrence, and that Myomectomy is unlikely to improve patient symptoms.